News
AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...
The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its ...
4d
Zacks Investment Research on MSNAstraZeneca Meets All Key Goals in Phase III Hypertension StudyAstraZeneca AZN reported positive top-line results from a late-stage study evaluating the safety, tolerability and efficacy ...
Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...
AstraZeneca (LSE:AZN) recently experienced a weekly price move of 2% amid announcements that could have supported its ...
Astra said its experimental drug Baxdrostat reduced the blood pressure of patients who have a treatment-resistant form of ...
The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...
At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients ...
4d
Clinical Trials Arena on MSNAstraZeneca’s Phase III trial of baxdrostat shows mean SBP reductionAstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.
AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...
AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...
AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results